How does your surveillance for DLBCL change given the new role of CAR-T in 2nd line treatment?  

There were at least 2 large studies from Europe showing that surveillance imaging for lymphoma patients in remission after completion of upfront treatments don’t improve survival (regardless of histology). I don’t usually get any imaging for DLBCL in remission after the end of treatment ...

Our surveillance has not changed. Patients are assessed with end of front line treatment imaging, clinically followed every 3 months, and radiographically followed every 6 months for the first two years. If new or progressive disease is found, we would biopsy for disease confirmation and then evalua...

Surveillance practices have not changed at this time. Patients are assessed for CAR T-cell therapy based on their eligibility from a disease perspective (number of lines of therapy, primary refractoriness, or early relapsed) and based on medical co-morbidities. Age is considered but not the only det...